Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - Arbutus Biopharma Corp | abus-20210331.htm |
| EX-32.2 - EX-32.2 - Arbutus Biopharma Corp | a2021-q110xqex322.htm |
| EX-31.2 - EX-31.2 - Arbutus Biopharma Corp | a2021-q110xqex312.htm |
| EX-31.1 - EX-31.1 - Arbutus Biopharma Corp | a2021-q110xqex311.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Arbutus Biopharma Corporation (the “Company”) for the quarter ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I William Collier, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly represents, in all material respects, the financial condition and results of the operations of the Company.
Date: May 5, 2021
| /s/ William Collier | |||||
| Name: William Collier | |||||
| Title: President and Chief Executive Officer | |||||